The Conversation (0)
Sunshine Biopharma Inc. (OTCQB:SBFM) announced that it has started negotiations with some Contract Manufacturing Organizations for the Good Manufacturing Practice manufacturing of a kilogram of the company’s premiere drug which will be used to treat breast cancer, Adva-27a.
Sunshine Biopharma Inc. (OTCQB:SBFM) announced that it has started negotiations with some Contract Manufacturing Organizations for the Good Manufacturing Practice manufacturing of a kilogram of the company’s premiere drug which will be used to treat breast cancer, Adva-27a.
As quoted in the press release:
The Company anticipates that one kilogram of Adva-27a will be sufficient to complete the upcoming IND-Enabling animal toxicity studies and Phase I clinical trials. These are required to be performed using the same GMP manufactured material. Following completion of the animal toxicity studies, the Company expects to file an Investigational New Drug (IND) application with the FDA (U.S. Food and Drug Administration) and wait for authorization to proceed with the planned Phase I clinical trial scheduled to be hosted at McGill University’s Jewish General Hospital in Montreal, Canada.
Click here to read the full Sunshine Biopharma Inc. (OTCQB:SBFM) press release.
